Subscribe to Newsletter
Business & Regulation Business Practice, COVID-19, Standards & Regulation, Small Molecules, Marketing

Seriously, Y’all. Stop It.

Earlier this year, I had a conversation with Mike Petroutsas – GSK’s Senior Vice President of US Oncology – about patient centricity, patient engagement, access to treatment, and disease awareness and education. Mike also talked about the rife misinformation about medicines and vaccines for COVID-19, and how it is important for the pharma industry to “build back trust in the healthcare system and in our medicines” (1).

A recent case in the US emphasizes his point. In August 2021, unvaccinated Jeffrey Smith was placed on a ventilator after becoming ill with COVID-19. His wife, Julie Smith, requested that he be treated with ivermectin (2). Ivermectin has attracted a great deal of attention in the research community for COVID-19, but it remains unproven. A preprint paper recently reported that ivermectin could reduce the chance of death in COVID-19 patients by more than 90 percent; however, the paper was later withdrawn due to flaws in the data (3). The FDA has created a page on its website titled “Why You Should Not Use Ivermectin to Treat or Prevent COVID-19 (4). In a tweet to promote the page (5), the FDA also said, “You are not a horse. You are not a cow. Seriously, y'all. Stop it.”

When the hospital refused to dispense ivermectin as a treatment, Julie filed a lawsuit to force treatment. On August 23, 2021, a judge ordered the hospital to treat the patient with ivermectin. In early September, the court order was overturned, with the judge stating that the medical and scientific communities do not support the use of ivermectin as a treatment for COVID-19.

Patients need to feel that they can trust medicine manufacturers and regulators, rather than seeking out other avenues where there is a strong risk of misinformation.

Smith’s case is not the first lawsuit around ivermectin and likely won’t be the last. Patients have rights and the pharma industry has often spoken of patient empowerment, but patients also need to be protected from clear misinformation and unproven medicines. Julie took advice from the Front Line COVID-19 Critical Care Alliance, a not-for-profit that believes ivermectin can successfully treat COVID-19 – and constantly seeks funding donations from the public. Members of the alliance wrote a paper promoting the benefits of ivermectin, but it was rejected for publication (6) (leading to an outcry of “censorship” from followers of the alliance). The alliance has had numerous posts removed from social media websites due to accusations of disseminating misinformation. 

There is a known trust issue in the pharma industry that must be addressed. Patients need to feel that they can trust medicine manufacturers and regulators, rather than seeking out other avenues where there is a strong risk of misinformation. Pharma companies must continue to improve their reputation amongst the public, ensuring that they are engaging with patients and giving patients information about medicines and diseases so that patients can make informed decisions – in collaboration with reputable healthcare practitioners, of course.

It's important not to mock cases like Julie’s. In the May issue of The Medicine Maker, Nicola Wainwright gave her opinion on the importance of open discussions about the risks and benefits of medical treatment – and how these can help counter problems such as vaccine hesitancy (7). “Unthinking criticism of those who are hesitant about the vaccine is not helpful – and it misses the point,” she wrote. “There are reasons they are hesitant – and those reasons need to be explored. For these concerned individuals, an honest and open discussion will be of considerable benefit. If nothing else, it can help counteract incorrect information obtained during uninformed discussions with friends and relatives, and from the conspiracy theories and scare-mongering that abounds, particularly on social media.”

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. The Medicine Maker, “Think of the Patients” (2021). Available at
  2. The Washington Post, “Ohio judge reverses colleague’s decision on covid patient’s ivermectin treatment: ‘Judges are not doctors’” (2021). Available at
  3. Nature, “Flawed ivermectin preprint highlights challenges of COVID drug studies,” (2021). Available at
  4. FDA, “Why You Should Not Use Ivermectin to Treat or Prevent COVID-19,” (2021). Available at
  5. Twitter, U.S. FDA (2021). Available at
  6. The Scientist, “Frontiers Removes Controversial Ivermectin Paper Pre-Publication,” (2021). Available at
  7. N Wainwright, “The Right to Decide,” The Medicine Maker (2021). Available at
About the Author
Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine